JPS6343367B2 - - Google Patents

Description

DETAILED DESCRIPTION OF THE INVENTION BACKGROUND OF THE INVENTION Technical Field The present invention relates to carbohydrate infusions. For more details,
An object of the present invention is to provide a carbohydrate infusion containing a reduced disaccharide. Maltitol or lactitol is used as the reduced disaccharide. Prior Art and its Problems Various carbohydrate infusions are commercially available, and are prepared using glucose, fructose, sorbitol, xylitol, and maltose as carbohydrates. With the exception of maltose, these carbohydrates are monosaccharides. In infusions where osmotic pressure must be taken into account, monosaccharides raise osmotic pressure approximately twice as much as disaccharides when added in the same weight amount. In addition, since maltose is a reducing sugar, it has an acetal structure in which the aldehyde group is masked in terms of its chemical structure, so it is not necessarily preferable because it has instability peculiar to compounds having an aldehyde group. Purpose of the Invention As a result of extensive research, the present inventors have succeeded in preparing a carbohydrate infusion containing maltitol and/or lactitol that is suitable as an intravenous infusion, and also found that the carbohydrate infusion can be used as a nutritional infusion. They discovered that it has excellent properties and completed the present invention. DETAILED DESCRIPTION OF THE INVENTION That is, the present invention is a carbohydrate infusion, which is characterized in that the infusion contains at least a reduced disaccharide in an aqueous solution. Desirably, the reduced disaccharide is maltitol and/or lactitol. The aqueous solution has a concentration range of elements in the sugar and electrolyte: Disaccharide reduction 50-350 g / Sodium 0-100 mmol / Potassium 10-60 mmol / Chlorine 0-100 mmol / Phosphorus 3-10 mmol / Magnesium 1-6 mmol / Calcium 1-6 mmol / Zinc 0-40 μmol / Chromium 0-1 μmol / Desirably. The maltitol used in the present invention is easily obtained by catalytic reduction or NaBH ₄ reduction of lactose. The carbohydrate infusion of the present invention can be obtained by adding a reduced disaccharide and, if necessary, an electrolyte shown in Table 1 to distilled water for injection and stirring.

[Table] Electrolytes containing sodium in Table 1 include NaCl, sodium lactate, and sodium citrate, and potassium includes KCl, K ₂ HPO ₄ ,
KH ₂ PO ₄ , potassium gluconate, potassium acetate,
For potassium citrate, magnesium
MgCl ₂ , MgSO ₄ , calcium lactate, CaCl ₂ , calcium gluconate, zinc ZnSO ₄ , ZnCl ₂ , chromium Cr(OAc) ₃ , CrCl ₂ among these. It can be selected and used as appropriate. The carbohydrate infusion of the present invention is filled into a vial, a plastic container inert to the infusion, the filling opening is then sealed, and the container is sterilized by high-pressure steam sterilization. Plastic containers are preferred as they are inert to the infusion because they do not generate flakes, and they also prevent contamination of the infusion due to contact with the outside air, and prevention of deterioration such as oxidation due to oxygen in the outside air. A plastic bag that is inert to the infusion is preferred since it does not require the introduction of outside air into the container. The bag may be made of soft vinyl chloride resin, ethylene/vinyl acetate copolymer, amide resin, or the like. The soft vinyl chloride resin is preferably one obtained by graft polymerizing or block polymerizing a plastic monomer to vinyl chloride, or one obtained by blending a plastic polymer with polyvinyl chloride. When sterilizing, gas is removed from the container before sterilization, so even if the reactivity of the infusion solution increases due to heat, there will be very little deterioration. When sterilizing an infusion solution filled in a plastic container using high-pressure steam, remove gases that are active against the infusion solution from around the container. Thus, the disadvantages of plastic containers, which have increased gas permeability, can be overcome. Specific Effects of the Invention It was confirmed that the carbohydrate infusion of the present invention has excellent nutritional supplementation effects when administered intravenously. Also,
Since the carbohydrate infusion does not directly administer glucose intravenously, it can be used as a therapeutic infusion for patients with decreased glucose tolerance. The present invention will be explained in more detail with reference to the following Examples and Test Examples. Example 1 The composition ratio shown in Table 2 was dissolved in sterilized distilled water under stirring. The resulting aqueous solution was adjusted to pH4.6 with lactic acid.
And so. After sterilizing the resulting aqueous solution,
After dispensing 500 ml into plastic bags and sealing them, they are sterilized using high-pressure steam at 121°C for 20 minutes to make carbohydrate infusions.

[Table] Test Example A catheter was placed in the jugular vein of a male Wistar rat weighing approximately 280 g. Divided into 3 groups, the first group received 18.8 ml of a commercially available carbohydrate infusion containing 25 W/V% glucose (trade name of high-calorie infusion manufactured by Terumo Corporation), continuously injected for 5 hours every day for 5 days. Then, 6 g (24.6 Kcal/day) of enteral nutritional supplement was administered enterally for 5 consecutive days. In the second group, 18.8 ml of the carbohydrate infusion prepared in Example 1 was injected every day for 5 hours for 5 days, and 6 g of the above enteral nutrition was administered enterally for 5 consecutive days. Group 3 is the above enteral nutrition 6 without infusion.
g was administered under the same conditions as the first and second groups. Each group was allowed free access to water. Changes in body weight in each group were examined. The results are shown in Table 3.
It became clear that there was almost no difference between the group and the second group, and weight loss was significantly suppressed compared to the third group. Table 3 Body weight change (g) 1st group -14.2±1.31 2nd group -13.7±1.27 3rd group -26.1±1.99 Example 2 Maltitol in Example 1 was replaced with lactitol, and the same composition ratio (molar ratio ) except that it is the same as Example 1.
It was the same. As a result, the same tendency as in Example 1 was observed. Example 3 Maltitol and lactitol were used separately or as a blend, and the solution concentration was adjusted to isotonic or higher, but the rest was the same as in Example 1. As a result, the same tendency as in Example 1 was observed. In addition, no disorders or toxic signs that were thought to be caused by the carbohydrate infusion of the present invention were observed in any of the Examples.

Claims (1)

[Scope of Claims] 1. A carbohydrate infusion, characterized in that the infusion contains at least a reduced disaccharide in an aqueous solution. 2. The carbohydrate infusion according to claim 1, wherein the reduced disaccharide is maltitol and/or lactitol. 3 The aqueous solution has a concentration range of elements in sugars and electrolytes: Disaccharide reduced product 50-350 g / Sodium 0-100 mmol / Potassium 10-60 mmol / Chlorine 0-100 mmol / Phosphorus 3-10 mmol / Magnesium 1-6 The carbohydrate infusion according to claim 1 or 2, wherein the sugar infusion solution is: mmol/calcium 1 to 6 mmol/zinc 0 to 40 micromol/chromium 0 to 1 micromol/.